CALQUENCE ® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial Read more
LIFT intersects 19 m at 1.31% Li2O at its Fi Southwest pegmatite & 23 m at 1.03% Li2O at its Echo pegmatite, Yellowknife Lithium Project, NWT Read more